Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Statistics
Share Statistics
Benitec Biopharma has 23.45M shares outstanding. The number of shares has increased by 795.54% in one year.
| Shares Outstanding | 23.45M |
| Shares Change (YoY) | 795.54% |
| Shares Change (QoQ) | 130.18% |
| Owned by Institutions (%) | 23.95% |
| Shares Floating | 21.97M |
| Failed to Deliver (FTD) Shares | 92 |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 56.89K, so 0.25% of the outstanding shares have been sold short.
| Short Interest | 56.89K |
| Short % of Shares Out | 0.25% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 1.35 |
Valuation Ratios
The PE ratio is -5.42 and the forward PE ratio is -1.14. Benitec Biopharma's PEG ratio is 0.09.
| PE Ratio | -5.42 |
| Forward PE | -1.14 |
| PS Ratio | 545.87 |
| Forward PS | 2 |
| PB Ratio | 2.5 |
| P/FCF Ratio | -6.02 |
| PEG Ratio | 0.09 |
Enterprise Valuation
Benitec Biopharma Inc. has an Enterprise Value (EV) of 3.71M.
| EV / Earnings | -0.17 |
| EV / Sales | 17.17 |
| EV / EBITDA | -0.16 |
| EV / EBIT | -0.16 |
| EV / FCF | -0.19 |
Financial Position
The company has a current ratio of 10.49, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.49 |
| Quick Ratio | 10.49 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.6 |
| Cash Flow / Debt | -68.32 |
| Interest Coverage | -24.88 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -46.01%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -46.01% |
| Revenue Per Employee | $13,500 |
| Profits Per Employee | $-1,359,437.5 |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -619K |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by 164.14% in the last 52 weeks. The beta is 0.92, so Benitec Biopharma's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | 164.14% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 9.8 |
| Relative Strength Index (RSI) | 60.49 |
| Average Volume (20 Days) | 51.73K |
Income Statement
In the last 12 months, Benitec Biopharma had revenue of 216K and earned -21.75M in profits. Earnings per share was -2.68.
| Revenue | 216K |
| Gross Profit | 108K |
| Operating Income | -22.49M |
| Net Income | -21.75M |
| EBITDA | -22.49M |
| EBIT | -22.49M |
| Earnings Per Share (EPS) | -2.68 |
Balance Sheet
The company has 50.87M in cash and 284K in debt, giving a net cash position of 50.58M.
| Cash & Cash Equivalents | 50.87M |
| Total Debt | 284K |
| Net Cash | 50.58M |
| Retained Earnings | -190.26M |
| Total Assets | 79.07M |
| Working Capital | 75.62M |
Cash Flow
In the last 12 months, operating cash flow was -19.4M and capital expenditures -179K, giving a free cash flow of -19.58M.
| Operating Cash Flow | -19.4M |
| Capital Expenditures | -179K |
| Free Cash Flow | -19.58M |
| FCF Per Share | -1.21 |
Margins
Gross margin is 50%, with operating and profit margins of -10.41K% and -10.07K%.
| Gross Margin | 50% |
| Operating Margin | -10.41K% |
| Pretax Margin | -10.36K% |
| Profit Margin | -10.07K% |
| EBITDA Margin | -10.41K% |
| EBIT Margin | -10.41K% |
| FCF Margin | -9.07K% |
Dividends & Yields
BNTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -21.41% |
| FCF Yield | -6.67% |
Analyst Forecast
The average price target for BNTC is $28, which is 123.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 123.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Jul 26, 2023. It was a backward split with a ratio of 1:17.
| Last Split Date | Jul 26, 2023 |
| Split Type | backward |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | 44.78 |
| Piotroski F-Score | 1 |